BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-83. [PMID: 19738092 DOI: 10.1001/jama.2009.1295] [Cited by in Crossref: 189] [Cited by in F6Publishing: 149] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Harnois D. Genetic Modifiers of Liver Disease in Cystic Fibrosis. Yearbook of Gastroenterology 2010;2010:259-60. [DOI: 10.1016/s0739-5930(10)79557-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Atlas AB, Rosh JR. Cystic Fibrosis and Congenital Anomalies of the Exocrine Pancreas. Pediatric Gastrointestinal and Liver Disease. Elsevier; 2011. pp. 890-904.e5. [DOI: 10.1016/b978-1-4377-0774-8.10081-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Zoller H, Wagner S, Tilg H. Is Heterozygosity for the Alpha-1 Antitrypsin Risk Allele Pi∗MZ a Disease Modifier or Genetic Risk Factor? Gastroenterology 2020;159:433-4. [DOI: 10.1053/j.gastro.2020.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Mogayzel PJ, Flume PA. Update in Cystic Fibrosis 2009. Am J Respir Crit Care Med 2010;181:539-44. [DOI: 10.1164/rccm.200912-1943up] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519-2531. [PMID: 27140670 DOI: 10.1016/s0140-6736(16)00576-6] [Cited by in Crossref: 740] [Cited by in F6Publishing: 364] [Article Influence: 123.3] [Reference Citation Analysis]
6 Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2017;8:CD012056. [PMID: 28850173 DOI: 10.1002/14651858.CD012056.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, Rand EB, Shaked A, Abt PL. Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data: Liver Transplantation in Patients with Cystic Fibrosis. Liver Transpl 2011;17:243-50. [DOI: 10.1002/lt.22240] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
8 Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. Glycobiology 2011;21:271-82. [PMID: 21045008 DOI: 10.1093/glycob/cwq161] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
9 Lobo J, Rojas-Balcazar JM, Noone PG. Recent advances in cystic fibrosis. Clin Chest Med 2012;33:307-28. [PMID: 22640848 DOI: 10.1016/j.ccm.2012.02.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
10 Sharma N, Cutting GR. The genetics and genomics of cystic fibrosis. J Cyst Fibros 2020;19 Suppl 1:S5-9. [PMID: 31879237 DOI: 10.1016/j.jcf.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Martin CR, Zaman MM, Ketwaroo GA, Bhutta AQ, Coronel E, Popov Y, Schuppan D, Freedman SD. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012;303:G474-81. [PMID: 22679000 DOI: 10.1152/ajpgi.00055.2012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
12 Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, Frawley K, Bell SC, Smith JL, Ramm GA. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011;53:193-201. [DOI: 10.1002/hep.24014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
13 Ledder O, Haller W, Couper RT, Lewindon P, Oliver M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol 2014;29:1954-62. [PMID: 25238538 DOI: 10.1111/jgh.12785] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
14 Costa PC, Barreto CC, Pereira L, Lobo ML, Costa MA, Lopes AI. Cystic fibrosis-related liver disease: a single-center experience. Pediatr Rep 2011;3:e21. [PMID: 22053265 DOI: 10.4081/pr.2011.e21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11:333-342; quiz e30-e31. [PMID: 23142604 DOI: 10.1016/j.cgh.2012.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
16 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
17 Farinha CM, Gentzsch M. Revisiting CFTR Interactions: Old Partners and New Players. Int J Mol Sci 2021;22:13196. [PMID: 34947992 DOI: 10.3390/ijms222413196] [Reference Citation Analysis]
18 Castaldo G, Tomaiuolo R. What is the role of the non-coding regions of the CFTR gene in cystic fibrosis? Expert Review of Respiratory Medicine 2014;7:327-9. [DOI: 10.1586/17476348.2013.814404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16:45-56. [PMID: 25404111 DOI: 10.1038/nrg3849] [Cited by in Crossref: 475] [Cited by in F6Publishing: 406] [Article Influence: 59.4] [Reference Citation Analysis]
20 Giordano S, Amato F, Elce A, Monti M, Iannone C, Pucci P, Seia M, Angioni A, Zarrilli F, Castaldo G, Tomaiuolo R. Molecular and functional analysis of the large 5' promoter region of CFTR gene revealed pathogenic mutations in CF and CFTR-related disorders. J Mol Diagn 2013;15:331-40. [PMID: 23470247 DOI: 10.1016/j.jmoldx.2013.01.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
21 Hadžić N, Baumann U, Mckiernan P, Mclin V, Nobili V. Long-term challenges and perspectives of pre-adolescent liver disease. The Lancet Gastroenterology & Hepatology 2017;2:435-45. [DOI: 10.1016/s2468-1253(16)30160-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
22 Castaldo G, Lembo F, Tomaiuolo R. Molecular diagnostics: between chips and customized medicine. Clin Chem Lab Med 2010;48:973-82. [PMID: 20441468 DOI: 10.1515/CCLM.2010.182] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, Riordan JR. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J 2013;27:536-45. [PMID: 23104983 DOI: 10.1096/fj.12-216119] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 9.8] [Reference Citation Analysis]
24 Jong T, Geake J, Yerkovich S, Bell SC. Idiosyncratic reactions are the most common cause of abnormal liver function tests in patients with cystic fibrosis. Intern Med J 2015;45:395-401. [PMID: 25644776 DOI: 10.1111/imj.12707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
25 Ooi CY, Dupuis A, Gonska T, Ellis L, Ni A, Jarvi K, Martin S, Ray P, Steele L, Kortan P, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P. Does Integration of Various Ion Channel Measurements Improve Diagnostic Performance in Cystic Fibrosis? Annals ATS 2014;11:562-70. [DOI: 10.1513/annalsats.201311-412oc] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 2016;14:1207-1215.e3. [PMID: 27062904 DOI: 10.1016/j.cgh.2016.03.041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
27 Raynal C, Corvol H. Variant classifications, databases and genotype-phenotype correlations. Arch Pediatr 2020;27 Suppl 1:eS13-8. [PMID: 32172930 DOI: 10.1016/S0929-693X(20)30045-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, Buzzetti R, Carnovale V, Casciaro R, Castaldo G, Cirilli N, Collura M, Colombo C, Di Lullo AM, Elce A, Lucidi V, Madarena E, Padoan R, Quattrucci S, Raia V, Seia M, Termini L, Zarrilli F. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018;18:196. [PMID: 30577776 DOI: 10.1186/s12890-018-0766-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
29 Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol 2012;19:250-62. [PMID: 22692288 DOI: 10.1097/PAP.0b013e31825c6a20] [Cited by in Crossref: 70] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
30 Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669-681. [PMID: 21045792 DOI: 10.1038/nrgastro.2010.170] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
31 Pollard BS, Pollard HB. Induced pluripotent stem cells for treating cystic fibrosis: State of the science. Pediatr Pulmonol 2018;53:S12-29. [PMID: 30062693 DOI: 10.1002/ppul.24118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
32 Van Biervliet S, Verdievel H, Vande Velde S, De Bruyne R, De Looze D, Verhelst X, Geerts A, Robberecht E, Van Vlierberghe H. Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. Ultrasound in Medicine & Biology 2016;42:848-54. [DOI: 10.1016/j.ultrasmedbio.2015.11.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
33 Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of Serum γ-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;61:113-8. [DOI: 10.1097/mpg.0000000000000758] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
34 Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S29-S36. [PMID: 21658639 DOI: 10.1016/s1569-1993(11)60006-4] [Cited by in Crossref: 233] [Cited by in F6Publishing: 69] [Article Influence: 21.2] [Reference Citation Analysis]
35 Karlsen TH, Hov JR. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol 2010;26:251-8. [PMID: 20042859 DOI: 10.1097/MOG.0b013e328336807d] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
36 Black SM, Woodley FW, Tumin D, Mumtaz K, Whitson BA, Tobias JD, Hayes D. Cystic Fibrosis Associated with Worse Survival After Liver Transplantation. Dig Dis Sci 2016;61:1178-85. [DOI: 10.1007/s10620-015-3968-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
37 Hirschfield GM. Genetic Determinants of Cholestasis. Clinics in Liver Disease 2013;17:147-59. [DOI: 10.1016/j.cld.2012.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
38 Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry: Pulmonary Function in Individuals with Cystic Fibrosis. Liver Transpl 2012;18:585-93. [DOI: 10.1002/lt.23389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
39 Garcia AM, Dorsey J. Nonpulmonary Manifestations of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 788-799.e3. [DOI: 10.1016/b978-0-323-44887-1.00052-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Wasuwanich P, Karnsakul W. Cystic fibrosis-associated liver disease in children.Minerva Pediatr. 2020;72:440-447. [PMID: 32418413 DOI: 10.23736/S0026-4946.20.05895-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Wilschanski M, Kerem E. New drugs for cystic fibrosis. Expert Opinion on Investigational Drugs 2011;20:1285-92. [DOI: 10.1517/13543784.2011.600304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
42 Narayanan P, Mistry PK. Update on Alpha-1 Antitrypsin Deficiency in Liver Disease. Clin Liver Dis (Hoboken). 2020;15:228-235. [PMID: 32617155 DOI: 10.1002/cld.896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 van Dorst JM, Tam RY, Ooi CY. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? Nutrients 2022;14:480. [DOI: 10.3390/nu14030480] [Reference Citation Analysis]
44 Marson FAL. Disease-modifying genetic factors in cystic fibrosis. Curr Opin Pulm Med 2018;24:296-308. [PMID: 29517584 DOI: 10.1097/MCP.0000000000000479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
45 Munck A, Languepin J, Debray D, Lamireau T, Abely M, Huet F, Maudinas R, Michaud L, Mas E. Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis. Revue des Maladies Respiratoires 2015;32:566-85. [DOI: 10.1016/j.rmr.2014.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
46 Weiler CA, Drumm ML. Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol. 2013;4:40. [PMID: 23630497 DOI: 10.3389/fphar.2013.00040] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
47 Dickinson KM, Collaco JM. Cystic Fibrosis. Pediatr Rev 2021;42:55-67. [PMID: 33526571 DOI: 10.1542/pir.2019-0212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
49 Debray D. L'atteinte hépatique de la mucoviscidose. Archives de Pédiatrie 2012;19:S23-6. [DOI: 10.1016/s0929-693x(12)71104-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med. 2012;2:a009548. [PMID: 23209180 DOI: 10.1101/cshperspect.a009548] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
51 Kosinski P, Kedzia M, Mostowska A, Gutaj P, Lipa M, Wender-Ozegowska E, Rozy A, Chorostowska-Wynimko J, Wielgos M, Jezela-Stanek A. Alpha-1 Antitrypsin Z Variant (AAT PI*Z) as a Risk Factor for Intrahepatic Cholestasis of Pregnancy. Front Genet 2021;12:720465. [PMID: 34557220 DOI: 10.3389/fgene.2021.720465] [Reference Citation Analysis]
52 Schaefer B, Mandorfer M, Viveiros A, Finkenstedt A, Ferenci P, Schneeberger S, Tilg H, Zoller H. Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transpl 2018;24:744-51. [PMID: 29573137 DOI: 10.1002/lt.25057] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
53 Morey RA, Hariri AR, Gold AL, Hauser MA, Munger HJ, Dolcos F, McCarthy G. Serotonin transporter gene polymorphisms and brain function during emotional distraction from cognitive processing in posttraumatic stress disorder. BMC Psychiatry 2011;11:76. [PMID: 21545724 DOI: 10.1186/1471-244X-11-76] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
54 Férec C, Scotet V, Beucher J, Corvol H. [Genetics and modifier genes, atypical and rare forms]. Arch Pediatr 2012;19 Suppl 1:S3-7. [PMID: 22682487 DOI: 10.1016/S0929-693X(12)71099-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Ling SC, Ye W, Leung DH, Navarro OM, Weymann A, Karnsakul W, Freeman AJ, Magee JC, Narkewicz MR. Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease. J Pediatr Gastroenterol Nutr 2019;69:351-7. [PMID: 31436672 DOI: 10.1097/MPG.0000000000002413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
56 Sosnay PR, Raraigh KS, Gibson RL. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype. Pediatr Clin North Am 2016;63:585-98. [PMID: 27469177 DOI: 10.1016/j.pcl.2016.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
57 Guerriero CJ, Brodsky JL. The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev 2012;92:537-76. [PMID: 22535891 DOI: 10.1152/physrev.00027.2011] [Cited by in Crossref: 246] [Cited by in F6Publishing: 239] [Article Influence: 24.6] [Reference Citation Analysis]
58 Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585-592. [PMID: 20955961 DOI: 10.1016/j.bpg.2010.08.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
59 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
60 Sommerburg O, Schenk JP. [Abdominal manifestations in cystic fibrosis : Clinical review]. Radiologe 2020;60:781-90. [PMID: 32776239 DOI: 10.1007/s00117-020-00729-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Arnon R, Annunziato RA, Miloh T, Padilla M, Sogawa H, Batemarco L, Willis A, Suchy F, Kerkar N. Liver and combined lung and liver transplantation for cystic fibrosis: Analysis of the UNOS database: Liver transplantation for cystic fibrosis. Pediatric Transplantation 2011;15:254-64. [DOI: 10.1111/j.1399-3046.2010.01460.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
62 Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: From pathophysiology to clinical practice. Journal of Hepatology 2015;62:S6-S14. [DOI: 10.1016/j.jhep.2015.02.025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
63 Brennan ML, Schrijver I. Cystic Fibrosis: A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas. J Mol Diagn. 2016;18:3-14. [PMID: 26631874 DOI: 10.1016/j.jmoldx.2015.06.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
64 Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017;74:129-140. [PMID: 27709245 DOI: 10.1007/s00018-016-2393-9] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 16.0] [Reference Citation Analysis]
65 Slae M, Wilschanski M. Cystic fibrosis and the gut. Frontline Gastroenterol 2021;12:622-8. [PMID: 34917319 DOI: 10.1136/flgastro-2020-101610] [Reference Citation Analysis]
66 Nash E, Volling C, Gutierrez C, Tullis E, Coonar A, Mcrae K, Keshavjee S, Singer L, Durie P, Chaparro C. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis*: Lung transplant with CF liver cirrhosis. Clinical Transplantation 2012;26:34-41. [DOI: 10.1111/j.1399-0012.2010.01395.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
67 Spagnolo P, Zeuzem S, Richeldi L, Du Bois RM. The complex interrelationships between chronic lung and liver disease: a review: Liver and lung disease associations. Journal of Viral Hepatitis 2010;17:381-90. [DOI: 10.1111/j.1365-2893.2010.01307.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
68 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
69 Zarrilli F, Elce A, Scorza M, Giordano S, Amato F, Castaldo G. An update on laboratory diagnosis of liver inherited diseases. Biomed Res Int 2013;2013:697940. [PMID: 24222913 DOI: 10.1155/2013/697940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
70 Jeyaraj R, Bounford KM, Ruth N, Lloyd C, MacDonald F, Hendriksz CJ, Baumann U, Gissen P, Kelly D. The Genetics of Inherited Cholestatic Disorders in Neonates and Infants: Evolving Challenges. Genes (Basel) 2021;12:1837. [PMID: 34828443 DOI: 10.3390/genes12111837] [Reference Citation Analysis]
71 Gallati S. Disease-modifying genes and monogenic disorders: experience in cystic fibrosis. Appl Clin Genet. 2014;7:133-146. [PMID: 25053892 DOI: 10.2147/tacg.s18675] [Cited by in Crossref: 55] [Cited by in F6Publishing: 28] [Article Influence: 6.9] [Reference Citation Analysis]
72 Anderson RH, Francis KR. Modeling rare diseases with induced pluripotent stem cell technology. Mol Cell Probes 2018;40:52-9. [PMID: 29307697 DOI: 10.1016/j.mcp.2018.01.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
73 Quaglia A, Roberts EA, Torbenson M. Developmental and Inherited Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 111-274. [DOI: 10.1016/b978-0-7020-6697-9.00003-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Karatas E, Bouchecareilh M. Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease. Clin Res Hepatol Gastroenterol 2021;45:101538. [PMID: 33069636 DOI: 10.1016/j.clinre.2020.09.003] [Reference Citation Analysis]
75 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Sathe MN, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis. Pediatr Clin North Am 2016;63:679-98. [PMID: 27469182 DOI: 10.1016/j.pcl.2016.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
77 Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, Ramm GA. Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 2012;54:328-35. [PMID: 22157922 DOI: 10.1097/MPG.0b013e3182432034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
78 Bolia R, Ooi CY, Lewindon P, Bishop J, Ranganathan S, Harrison J, Ford K, van der Haak N, Oliver MR. Practical approach to the gastrointestinal manifestations of cystic fibrosis. J Paediatr Child Health 2018;54:609-19. [PMID: 29768684 DOI: 10.1111/jpc.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Polineni D, Piccorelli AV, Hannah WB, Dalrymple SN, Pace RG, Durie PR, Ling SC, Knowles MR, Stonebraker JR. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population. PLoS One 2018;13:e0205257. [PMID: 30307979 DOI: 10.1371/journal.pone.0205257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
80 Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ. Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition 2014;59:476-9. [DOI: 10.1097/mpg.0000000000000448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
81 Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel PR, Desmazes-Dufeu N, Soubrane O, Dusser D, Sogni P. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011;55:1377-82. [PMID: 21703187 DOI: 10.1016/j.jhep.2011.03.028] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
82 Dowman JK, Watson D, Loganathan S, Gunson BK, Hodson J, Mirza DF, Clarke J, Lloyd C, Honeybourne D, Whitehouse JL, Nash EF, Kelly D, van Mourik I, Newsome PN. Long-Term Impact of Liver Transplantation on Respiratory Function and Nutritional Status in Children and Adults With Cystic Fibrosis: Lung Function After Liver Transplant in CF. American Journal of Transplantation 2012;12:954-64. [DOI: 10.1111/j.1600-6143.2011.03904.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
83 Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 2014;133:151-61. [PMID: 24057835 DOI: 10.1007/s00439-013-1363-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
84 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
85 Nightingale S, O'Loughlin EV, Dorney SF, Shun A, Verran DJ, Strasser SI, McCaughan GW, Jermyn V, Van Asperen P, Gaskin KJ, Stormon MO. Isolated liver transplantation in children with cystic fibrosis--an Australian experience. Pediatr Transplant 2010;14:779-85. [PMID: 20557476 DOI: 10.1111/j.1399-3046.2010.01341.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
86 Hamesch K, Strnad P. Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:260-71. [PMID: 32697896 DOI: 10.15326/jcopdf.7.3.2019.0161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
88 Manco M, Zupone CL, Alghisi F, D'andrea ML, Lucidi V, Monti L. Pilot study on the use of acoustic radiation force impulse imaging in the staging of cystic fibrosis associated liver disease. Journal of Cystic Fibrosis 2012;11:427-32. [DOI: 10.1016/j.jcf.2012.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
89 Ye W, Leung DH, Molleston JP, Ling SC, Murray KF, Nicholas JL, Huang S, Karmazyn BW, Harned RK, Masand P, Alazraki AL, Navarro OM, Otto RK, Palermo JJ, Towbin AJ, Alonso EM, Karnsakul WW, Jane Schwarzenberg S, Seidel GF, Siegel M, Magee JC, Narkewicz MR, Jay Freeman A. Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis. Hepatol Commun 2021;5:1362-72. [PMID: 34430781 DOI: 10.1002/hep4.1719] [Reference Citation Analysis]
90 Ruiz M, Lacaille F, Berthiller J, Joly P, Dumortier J, Aumar M, Bridoux‐henno L, Jacquemin E, Lamireau T, Broué P, Rivet C, Belmalih A, Restier L, Chapuis‐cellier C, Bouchecareilh M, Lachaux A, Tacke F; Groupe Francophone d’Hépatologie Gastroentérologie et Nutrition Pédiatriques. Liver disease related to alpha1‐antitrypsin deficiency in French children: The DEFI‐ALPHA cohort. Liver Int 2019;39:1136-46. [DOI: 10.1111/liv.14035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
91 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
92 Sellers ZM, Lee LW, Barth RA, Milla C. New Algorithm for the Integration of Ultrasound Into Cystic Fibrosis Liver Disease Screening. Journal of Pediatric Gastroenterology & Nutrition 2019;69:404-10. [DOI: 10.1097/mpg.0000000000002412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
93 Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol 2016;13:175-85. [DOI: 10.1038/nrgastro.2015.226] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
94 Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS One 2019;14:e0212779. [PMID: 30947265 DOI: 10.1371/journal.pone.0212779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
95 Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. Journal of Cystic Fibrosis 2017;16:139-45. [DOI: 10.1016/j.jcf.2016.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
96 Sofia VM, Da Sacco L, Surace C, Tomaiuolo AC, Genovese S, Grotta S, Gnazzo M, Ciocca L, Petrocchi S, Alghisi F, Montemitro E, Martemucci L, Elce A, Lucidi V, Castaldo G, Angioni A. Extensive molecular analysis suggested the strong genetic heterogeneity of idiopathic chronic pancreatitis. Mol Med 2016;22:300-9. [PMID: 27264265 DOI: 10.2119/molmed.2016.00010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
97 Rudnick DA. Cystic fibrosis-associated liver disease: when will the future be now? J Pediatr Gastroenterol Nutr 2012;54:312. [PMID: 21832947 DOI: 10.1097/MPG.0b013e3182309fd0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Hohwieler M, Perkhofer L, Liebau S, Seufferlein T, Müller M, Illing A, Kleger A. Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis. United European Gastroenterol J 2017;5:609-24. [PMID: 28815024 DOI: 10.1177/2050640616670565] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
99 Rohlfs EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, Flynn K, Scholl T, Akmaev VR, Sirko-Osadsa DA, Allitto BA, Sugarman EA. Cystic fibrosis carrier testing in an ethnically diverse US population. Clin Chem 2011;57:841-8. [PMID: 21474639 DOI: 10.1373/clinchem.2010.159285] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
100 Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019;13:23-38. [PMID: 30472915 DOI: 10.1080/17476348.2019.1552832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci. 2010;1214:57-69. [PMID: 21175684 DOI: 10.1111/j.1749-6632.2010.05879.x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 161] [Article Influence: 16.1] [Reference Citation Analysis]
102 Wilk MA, Braun AT, Farrell PM, Laxova A, Brown DM, Holt JM, Birch CL, Sosonkina N, Wilk BM, Worthey EA. Applying whole-genome sequencing in relation to phenotype and outcomes in siblings with cystic fibrosis. Cold Spring Harb Mol Case Stud 2020;6:a004531. [PMID: 32014855 DOI: 10.1101/mcs.a004531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Leung DH, Heltshe SL, Borowitz D, Gelfond D, Kloster M, Heubi JE, Stalvey M, Ramsey BW; Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life. JAMA Pediatr 2017;171:546-54. [PMID: 28437538 DOI: 10.1001/jamapediatrics.2017.0206] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
104 Carrion AF, Bhamidimarri KR. Liver transplant for cholestatic liver diseases. Clin Liver Dis. 2013;17:345-359. [PMID: 23540507 DOI: 10.1016/j.cld.2012.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
105 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Joly P, Restier L, Bouchecareilh M, Lacan P, Cabet F, Chapuis-cellier C, Francina A, Lachaux A. Cohorte DEFI-ALPHA et projet hospitalier de recherche clinique POLYGEN DEFI-ALPHA. Étude des facteurs cliniques, biologiques et génétiques associés à l’apparition et à l’évolution de complications hépatiques chez les enfants présentant un déficit en alpha-1 antitrypsine. Revue des Maladies Respiratoires 2015;32:759-67. [DOI: 10.1016/j.rmr.2015.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Singh H, Coffey MJ, Ooi CY. Cystic Fibrosis-related Liver Disease is Associated With Increased Disease Burden and Endocrine Comorbidities. J Pediatr Gastroenterol Nutr 2020;70:796-800. [PMID: 32443033 DOI: 10.1097/MPG.0000000000002694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Louden ED, Poch A, Kim HG, Ben-Mahmoud A, Kim SH, Layman LC. Genetics of hypogonadotropic Hypogonadism-Human and mouse genes, inheritance, oligogenicity, and genetic counseling. Mol Cell Endocrinol 2021;534:111334. [PMID: 34062169 DOI: 10.1016/j.mce.2021.111334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Palaniappan SK, Than NN, Thein AW, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2020;3:CD012056. [PMID: 32227478 DOI: 10.1002/14651858.CD012056.pub3] [Reference Citation Analysis]
110 Ayoub F, Li H, Blay C, Trillo-Alvarez C, Lascano J, Morelli G. Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In? Clin Liver Dis (Hoboken) 2019;14:187-90. [PMID: 31879562 DOI: 10.1002/cld.845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
111 Ye W, Narkewicz MR, Leung DH, Karnsakul W, Murray KF, Alonso EM, Magee JC, Schwarzenberg SJ, Weymann A, Molleston JP; CFLDnet research group. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis. J Pediatr Gastroenterol Nutr 2018;66:122-7. [PMID: 28906321 DOI: 10.1097/MPG.0000000000001728] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
112 Ooi CY, Nightingale S, Durie PR, Freedman SD. Ursodeoxycholic acid in cystic fibrosis-associated liver disease. J Cyst Fibros 2012;11:72-3; author reply 74-75. [PMID: 21862443 DOI: 10.1016/j.jcf.2011.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
113 Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ 2012;184:1365-71. [PMID: 22761482 DOI: 10.1503/cmaj.111749] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
114 Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-49. [PMID: 25093717 DOI: 10.3390/ijms150813529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
115 Schneider CV, Hamesch K, Gross A, Mandorfer M, Moeller LS, Pereira V, Pons M, Kuca P, Reichert MC, Benini F, Burbaum B, Voss J, Gutberlet M, Woditsch V, Lindhauer C, Fromme M, Kümpers J, Bewersdorf L, Schaefer B, Eslam M, Bals R, Janciauskiene S, Carvão J, Neureiter D, Zhou B, Wöran K, Bantel H, Geier A, Dirrichs T, Stickel F, Teumer A, Verbeek J, Nevens F, Govaere O, Krawczyk M, Roskams T, Haybaeck J, Lurje G, Chorostowska-Wynimko J, Genesca J, Reiberger T, Lammert F, Krag A, George J, Anstee QM, Trauner M, Datz C, Gaisa NT, Denk H, Trautwein C, Aigner E, Strnad P; European Alpha-1 Liver Study Group. Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers. Gastroenterology 2020;159:534-548.e11. [PMID: 32376409 DOI: 10.1053/j.gastro.2020.04.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
116 Fromme M, Oliverius M, Strnad P. DEFI-ALFA: The French key to the alpha1 mystery? Liver Int 2019;39:1019-21. [PMID: 31127687 DOI: 10.1111/liv.14064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Nascimento FS, Sena NA, Ferreira TDA, Marques CDF, Silva LR, Souza EL. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr (Rio J) 2018;94:504-10. [PMID: 28888897 DOI: 10.1016/j.jped.2017.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
118 Balfour-Lynn IM. Personalised medicine in cystic fibrosis is unaffordable. Paediatr Respir Rev 2014;15 Suppl 1:2-5. [PMID: 24832698 DOI: 10.1016/j.prrv.2014.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
119 Cao JY, Artunduaga M, Schooler GR. Hepatic manifestations of systemic disease: an imaging-based review. Pediatr Radiol 2021. [PMID: 34797394 DOI: 10.1007/s00247-021-05222-5] [Reference Citation Analysis]
120 Zarei K, Stroik MR, Gansemer ND, Thurman AL, Ostedgaard LS, Ernst SE, Thornell IM, Powers LS, Pezzulo AA, Meyerholz DK, Stoltz DA. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Lab Invest 2020;100:1388-99. [PMID: 32719544 DOI: 10.1038/s41374-020-0474-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
122 Flemming G, Baumann U, Richter N, Vondran F, Tümmler B, Dittrich AM, Müller C, Vogel M, Pfister ED. Survival Benefits Following Liver Transplantation: A Matched-pair Analysis in Pediatric Patients With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2021;73:385-90. [PMID: 34091543 DOI: 10.1097/MPG.0000000000003194] [Reference Citation Analysis]
123 Smith DJ, Klein K, Hartel G, Wainwright CE, Bell SC, Anderson GJ, Reid DW. Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene 2019;683:12-7. [DOI: 10.1016/j.gene.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
124 Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One 2015;10:e0116967. [PMID: 25658710 DOI: 10.1371/journal.pone.0116967] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
125 Debray D, Corvol H, Housset C. Modifier genes in cystic fibrosis-related liver disease. Curr Opin Gastroenterol 2019;35:88-92. [PMID: 30585791 DOI: 10.1097/MOG.0000000000000508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
126 Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR; Cystic Fibrosis Liver Disease Network (CFLD NET). Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr 2015;167:862-868.e2. [PMID: 26254836 DOI: 10.1016/j.jpeds.2015.06.062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
127 Jassal MS, Yu AM, Bhatia R, Keens TG, Davidson Ward SL. Effect of residential proximity to major roadways on cystic fibrosis exacerbations. Int J Environ Health Res 2013;23:119-31. [PMID: 22838501 DOI: 10.1080/09603123.2012.708917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
128 Boëlle PY, Debray D, Guillot L, Corvol H; French CF Modifier Gene Study Investigators. SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genet Med 2019;21:2151-5. [PMID: 30739910 DOI: 10.1038/s41436-019-0449-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
129 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
130 Debray D, El Mourabit H, Merabtene F, Brot L, Ulveling D, Chrétien Y, Rainteau D, Moszer I, Wendum D, Sokol H, Housset C. Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatol Commun 2018;2:1533-49. [PMID: 30556040 DOI: 10.1002/hep4.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
131 Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK; International PSC Study Group, The UK PSC Consortium. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut 2018;67:1517-24. [PMID: 28779025 DOI: 10.1136/gutjnl-2016-313598] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
132 Leung DH, Yimlamai D. The intestinal microbiome and paediatric liver disease. Lancet Gastroenterol Hepatol 2017;2:446-55. [PMID: 28497760 DOI: 10.1016/S2468-1253(16)30241-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
133 Rowland M, Bourke B. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2011;17:461-6. [PMID: 21881510 DOI: 10.1097/MCP.0b013e32834b7f51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
134 Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med 2013;1:148-57. [PMID: 24429095 DOI: 10.1016/S2213-2600(13)70026-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 5.9] [Reference Citation Analysis]
135 Marson FA, Bertuzzo CS, Hortencio TD, Ribeiro JD, Bonadia LC, Ribeiro AF. The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulm Med 2012;12:41. [PMID: 22874010 DOI: 10.1186/1471-2466-12-41] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
136 Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Liver Transpl 2019;25:640-57. [PMID: 30697907 DOI: 10.1002/lt.25421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Greene CM, Hassan T, Molloy K, McElvaney NG. The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Rev Respir Med 2011;5:395-411. [PMID: 21702661 DOI: 10.1586/ers.11.20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
138 Bandsma R, Bozic M, Fridell J, Crull M, Molleston J, Avitzur Y, Mozer-glassberg Y, Gonzalez-peralta R, Hodik M, Fecteau A, de Angelis M, Durie P, Ng V. Simultaneous liver–pancreas transplantation for cystic fibrosis-related liver disease: A multicenter experience. Journal of Cystic Fibrosis 2014;13:471-7. [DOI: 10.1016/j.jcf.2013.12.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
139 Strnad P, Schneider CV, Clark V. Clinical approach to liver disease in adults with AATD. In: Strnad P, Brantly ML, Bals R, editors. α 1 -Antitrypsin Deficiency. Sheffield: European Respiratory Society; 2019. pp. 114-26. [DOI: 10.1183/2312508x.10033018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Blackman SM, Commander CW, Watson C, Arcara KM, Strug LJ, Stonebraker JR, Wright FA, Rommens JM, Sun L, Pace RG, Norris SA, Durie PR, Drumm ML, Knowles MR, Cutting GR. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 2013;62:3627-35. [PMID: 23670970 DOI: 10.2337/db13-0510] [Cited by in Crossref: 104] [Cited by in F6Publishing: 85] [Article Influence: 11.6] [Reference Citation Analysis]
141 Davison S. Assessment of liver disease in cystic fibrosis. Paediatr Respir Rev 2018;27:24-7. [PMID: 29933897 DOI: 10.1016/j.prrv.2018.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
142 Kelly T, Buxbaum J. Gastrointestinal Manifestations of Cystic Fibrosis. Dig Dis Sci 2015;60:1903-13. [DOI: 10.1007/s10620-015-3546-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
143 Hakim A, Moll M, Qiao D, Liu J, Lasky-Su JA, Silverman EK, Vilarinho S, Jiang ZG, Hobbs BD, Cho MH. Heterozygosity of the Alpha 1-Antitrypsin Pi*Z Allele and Risk of Liver Disease. Hepatol Commun 2021;5:1348-61. [PMID: 34430780 DOI: 10.1002/hep4.1718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
145 Cutting GR. Cystic Fibrosis. Emery and Rimoin's Principles and Practice of Medical Genetics. Elsevier; 2013. pp. 1-54. [DOI: 10.1016/b978-0-12-383834-6.00062-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Freudenberg F, Leonard MR, Liu SA, Glickman JN, Carey MC. Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010;299:G205-14. [PMID: 20430874 DOI: 10.1152/ajpgi.00341.2009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
147 Petrowsky H, Brunicardi FC, Leow VM, Venick RS, Agopian V, Kaldas FM, Zarrinpar A, Markovic D, Mcdiarmid SV, Hong JC, Farmer DG, Hiatt JR, Busuttil RW. Liver Transplantation for Lethal Genetic Syndromes: A Novel Model of Personalized Genomic Medicine. Journal of the American College of Surgeons 2013;216:534-43. [DOI: 10.1016/j.jamcollsurg.2012.12.050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
148 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015;308:G459-71. [PMID: 25591863 DOI: 10.1152/ajpgi.00146.2014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
149 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
150 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
151 Houwen RH, van der Woerd WL, Slae M, Wilschanski M. Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis. Current Opinion in Pulmonary Medicine 2017;23:551-5. [DOI: 10.1097/mcp.0000000000000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
152 Siegel MJ, Freeman AJ, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J, Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM, Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR; CFLD Network. Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study. J Pediatr 2020;219:62-69.e4. [PMID: 32061406 DOI: 10.1016/j.jpeds.2019.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
153 Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child 2014;99:443-7. [PMID: 24436365 DOI: 10.1136/archdischild-2013-304159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
154 Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. Can J Gastroenterol Hepatol. 2015;29:139-144. [PMID: 25855877 DOI: 10.1155/2015/138530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
155 Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol 2021:S0168-8278(21)02227-3. [PMID: 34848258 DOI: 10.1016/j.jhep.2021.11.022] [Reference Citation Analysis]
156 Terlizzi V, Carnovale V, Castaldo G, Castellani C, Cirilli N, Colombo C, Corti F, Cresta F, D'Adda A, Lucarelli M, Lucidi V, Macchiaroli A, Madarena E, Padoan R, Quattrucci S, Salvatore D, Zarrilli F, Raia V. Clinical expression of patients with the D1152H CFTR mutation. J Cyst Fibros 2015;14:447-52. [PMID: 25583415 DOI: 10.1016/j.jcf.2014.12.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
157 Zarei K, Meyerholz DK, Stoltz DA. Early intrahepatic duct defects in a cystic fibrosis porcine model. Physiol Rep 2021;9:e14978. [PMID: 34288572 DOI: 10.14814/phy2.14978] [Reference Citation Analysis]
158 Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, de Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade HJ. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65:443-448. [PMID: 28753176 DOI: 10.1097/mpg.0000000000001676] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 12.3] [Reference Citation Analysis]
159 Kuscuoglu D, Bewersdorf L, Wenzel K, Gross A, Kobazi Ensari G, Luo Y, Kilic K, Hittatiya K, Golob-Schwarzl N, Leube RE, Preisinger C, George J, Metwally M, Eslam M, Lampertico P, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Loglio A, Sutton A, Nahon P, Schaefer B, Zoller H, Aigner E, Trautwein C, Haybaeck J, Strnad P. Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. J Pathol 2021;254:80-91. [PMID: 33586163 DOI: 10.1002/path.5643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros 2020;19 Suppl 1:S10-4. [PMID: 31734115 DOI: 10.1016/j.jcf.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]